ArticleFrontiers in endocrinology2026
Residual cholesterol correlates with mild cognitive impairment, particularly for executive dysfunction among male individuals with type 2 diabetes mellitus.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Residual cholesterol (RC) is derived from lipids, especially for cholesterol metabolism indexes, correlated with excessive nutrient intake, has recently been suggested to influence cognitive function. It not only reflects the nutrition metabolism status, but also is closely associated with diabetic complications. Despite this, how this nutrition-related metabolic marker relates to cognitive dysfunction in type 2 diabetes mellitus (T2DM) patients is still poorly understood. This study sought to assess the link between RC levels and mild cognitive impairment (MCI) among those living with T2DM. Methods: A total of 195 individuals with T2DM participated in the study and were divided by cognitive status into a normal cognition control group and an MCI group. Between these two cohorts, baseline features were compared. To determine the association between RC and cognitive impairment, both correlation analysis and logistic regression were applied. Sex-based subgroup analyses were conducted, and ROC curve analysis was used to evaluate the diagnostic performance of RC in detecting MCI. Results: RC levels were notably higher in individuals with MCI than in their cognitively normal counterparts. Even after accounting for age, sex, and how long diabetes had lasted, elevated RC stood out as an independent risk factor for MCI. Among males, RC showed a negative link with MoCA scores-a marker of overall cognitive performance-as well as with verbal fluency test results, pointing to executive deficits. No such relationship emerged in females. According to ROC curve analysis, an RC cutoff of 0.675 mmol/L yielded 80.0% sensitivity and 68.3% specificity (AUC = 0.784) for detecting MCI in the male subgroup. Conclusions: In male patients with T2DM, elevated RC is one of the risk factors for early cognitive dysfunction, especially affecting the executive function, and a promising biomarker for MCI detection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.